{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005555","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.568895+00:00","generated_at":"2026-05-17T10:42:56.436078+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Aptose appoints EY as auditor, receives $1.5M advance from Hanmi for AML drug","bullets":["Shareholders voted to appoint Ernst & Young as independent auditor at reconvened annual meeting.","Received additional $1.5M advance from Hanmi under $8.5M loan facility, total drawn now $7.1M.","Funds support continued clinical development of tuspetinib-based triplet therapy for AML.","Aptose is a clinical-stage oncology company focused on front-line AML treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005555","json":"https://secwatch.observer/filing/0001171843-25-005555.json","markdown":"https://secwatch.observer/filing/0001171843-25-005555.md","text":"https://secwatch.observer/filing/0001171843-25-005555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005555/0001171843-25-005555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325005555/f8k_082225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:42:56.436078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}